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Grapefruit juice (GJ) is a well known Cytochrome P450 (CYP) inhibitor; CYP3A is one of the most affected
subfamily leading to anticarcinogenic and antimutagenic effects when GJ is administered to experimental
animals in combinationwithmutagenic/carcinogenic agentsmetabolized by CYP3A. Bergamottin, naringin
and dihydroxybergamottin are three main constituents contained within GJ and their inhibitory effect
against CYP3A4 has been well documented. Reports suggest that CYP3A is not the only one affected but
CYP1A and 2B are also affected by GJ. To explore this last possibility in depthwe tested the in vitro capacity
of bergamottin, naringin and dihydroxybergamottin to inhibit the activity of CYP1A and 2B subfamilies and
found that bergamottin showed the strongest inhibitory effect and naringin showed no inhibition at all.
Therefore, we decided to biochemically characterize the inhibitory properties of bergamottin. CYP1A1 Sup-
ersome used in this study showed a Kmapp = 0.0723 lMand a Vmapp = 6.141 lU/pmolwith substrate eth-
oxyresoruﬁn, and the biochemical characterization of bergamottin CYP1A1 inhibitory effect revealed that it
is a competitive inhibitorwith a Ki = 10.703 nM.We also conﬁrmed the antimutagenicity of this compound
against the mutagenic effect of 3-methylcholanthrene and benzo[a]pyrene in the Ames test.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
CYP is a family of haem containing enzymes involved in the bio-
transformation of xenobiotics as well as endogenous molecules
(Fujii-Kuriyama and Kawajiri, 2010). Proteins belonging to CYP
can be classiﬁed according to their amino acid sequence in fami-
lies, subfamilies and isoforms following the suggestion of Nelson
et al. (1996). CYP1A and CYP2B subfamilies are particularly impor-
tant due to their capacity to ‘‘activate’’ a broad variety of environ-
mental contaminants leading to highly reactive metabolites that
react with macromolecules like proteins, lipids and nucleic acids
(Nebert, 1989; Rendic, 2002). CYP1A1, one of the two members
belonging to the CYP1A subfamily, is able to metabolize polycyclic
aromatic hydrocarbons (PAH’s) that are ubiquitous compounds
found in petroleum and emissions from fossil fuels combustion,
in charred meat and ﬁsh cooked directly over ﬁre, in tobacco
smoke and several other products resulting from the incomplete
combustion of organic matter (Jeffy et al., 2002). It is well known
that the metabolites formed from CYP1A1 and PAH´s interaction
generate DNA-adducts leading to mutagenic events and chromo-de Medicina Genómica y
es Biomédicas, Universidad
04510 México D.F., Mexico.
inosa-Aguirre).
Y-NC-ND license.some aberrations that can contribute to the carcinogenic process
(Shou et al., 1996). On the other hand, CYP1A2, the additional
member of the CYP1A subfamily, is also involved in the metabo-
lism of drugs including clozapine, theophylline, tacrine and verap-
amil among others (Zhou et al., 2010). Therefore, alteration of the
CYP1A2 basal activity may cause clinically important drug–drug
and food–drug interactions (Granfors et al., 2004; Hu et al., 2005).
The study of grapefruit juice (GJ) interaction with several drugs,
as well as its possible beneﬁts to humans as a chemoprotective
agent, has increased over the years since it was ﬁrst reported as
a potent inhibitor of some CYP isoforms (Seden et al., 2010). GJ
not only inhibits CYP metabolism but also inhibits the activity of
transporter proteins that alleviate cells from the accumulation of
toxic substances (Dresser et al., 2002; Takanaga et al., 1998). Fur-
thermore, some of the GJ components modulate also the expres-
sion of phase II enzymes (Kleiner et al., 2008). Among the most
abundant molecules found in GJ, are naringin (NG), bergamottin
(BG) and dihydroxybergamottin (DHB), and all have been reported
as CYP inhibitors (De Castro et al., 2006). NG is a ﬂavonoid found in
GJ at concentrations ranging from 174 to 1472 lmol/L (De Castro
et al., 2006); it can be metabolized by a-ranmosidase and b-gluco-
sidase to naringenin (NGN) that inhibits CYP3A4 activity (Fuhr and
Kummert, 1995; Kane and Lipsky, 2000). In vitro experiments using
human liver microsomes have shown that NG displays a poor inhi-
bition over CYP3A4 and CYP1A2 activities in comparison to the
inhibitory effect displayed by the whole GJ (Bailey et al., 1993;
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rez-Gonzalez et al. (2001), reported that NG decreased the micro-
nuclei induced by ifosfamide in mouse showing an in vivo
chemoprotective effect associated to the inhibition of Cyp3a. Addi-
tionally, NG protected against the hepatic damage caused by nickel
administered p.o. to the rat (Pari and Amudha, 2011).
BG and DHB are furocoumarins found in GJ at concentrations in
the range of 1.0–36.6 and 0.22–52.6 lmol/L, respectively (De Castro
et al., 2006). It has been reported that DHB displays greater inhibi-
tory potency over CYP3A4, CYP2C9 and CYP2D6 than does BG (Gir-
ennavar et al., 2007). Besides, it is also well known that BG provokes
an irreversible inhibition of CYP3A4, CYP2A6, CYP3A5 and CYP2B6,
thus modifying the metabolism of substrates of these enzymes (Lin
et al., 2005). Using microsomes obtained from rat hepatic cells as a
source of CYP1A1 activity, the reported 50% inhibitory concentra-
tion (IC50) for BG is 10  109 M (Baumgart et al., 2005), that is
one order ofmagnitude different to that obtainedwithmouse hepa-
ticmicrosomes (1.24  107 M) (Cai et al., 1993). In this last study, it
was determined that BG acts as a non-competitive inhibitor with a
Ki = 2.83  107 M. Nevertheless, the biochemical characterization
of such inhibition using puriﬁed enzyme preparations has not been
reported. Furocoumarin dimers are also present as minor constitu-
ents in grapefruit juice (Fukuda et al., 1997), they were identiﬁed as
themost potent inhibitors of CYP3A4 activity (Guo et al., 2000; Tass-
aneeyakul et al., 2000).
It is important to note that psoralen and 8-methoxypsoralen (8-
MOP) are furocoumarins of natural origin that have been classiﬁed
as human carcinogens in class 1A according to the IARC classiﬁca-
tion (IARC, 1986). Both of them are used as therapeutic drugs for
the treatment of psoriasis in combination with UVA irradiation;
this therapy is able to induce skin tumors under certain circum-
stances (Stern and Nichols, 1996). Studies on the phototoxicity
and photogenotoxicity of furocoumarins have revealed that psora-
len, 8-MOP and 5-methoxypsoralen, are among the most toxic fur-
ocoumarins, whereas BG seem to lack any UVA-dependent
signiﬁcant effect in V79 cells in culture (Lohr et al., 2010; Messer
et al., 2012).
The ability of BG to inhibit CYP has been used to study its anti-
genotoxic effects in in vivo and in vitro models. BG abolishes skin
cancer initiation in mice and adducts formation in keratinocytes,
MCF-7 and HEPA-1 cells in culture due to BP and dimethylbezan-
thracene treatments (Kleiner et al., 2002, 2003; Cai et al., 1997).
These results are the basis to consider BG as a potential chemopro-
tective agent.
In spite of the numerous studies focused on the inhibition of
CYP families, there are only a few exploring the possible inhibitory
effect of BG on CYP1A and 2B subfamilies which are important be-
cause they are involved in the metabolism of several mutagens/
carcinogens as well as some pharmaceuticals. Furthermore, as far
as we know, there is not a study that integrates both, the biochem-
ical characterization of the inhibitory action of BG on CYP1A and
CYP2B subfamilies and the biological consequences of such inhibi-
tion. The goal of this study is to explore the inhibitory effects of BG,
DHB and NG on CYP1A1, CYP1A2, CYP2B1 and CYP2B2 isozymes, to
biochemically characterize the inhibition properties of the stron-
gest inhibitor, BG, and to analyze a biological effect of such inhibi-
tion in the Salmonella/microsome mutagenicity test.2. Materials and methods
2.1. Materials
Bergamottin (BG) was purchased from INDOFINE Chemical Company Inc. (Hills-
borough, NJ, USA). Phenobarbital (PB) was purchased from ABOTT Laboratories in
Mexico (Mexico City, Mexico). b-Naphtoﬂavone (b-NF), resoruﬁn, 7-ethoxyresoruﬁn
(ER), methoxyresoruﬁn (MR), benzyloxiresoruﬁn (BR), penthoxyresoruﬁn (BR),
naringin (NG), 7,8-dihydroxybergamottin (DHB), NADPH, benzo[a]pyrene (BP), cornoil, and Giemsa were purchased from Sigma Chemicals Co. (St. Louis MO, USA).
Microsomes of Baculovirus expression systems from insect cell (supersomes)
expressing rat CYP1A1 were purchased from BD-Gentest (Woburn, MA, USA).2.2. Animal treatments
Male Wistar rats (weighing 250 g) were housed in polypropylene cages and
kept in a 12 h light cycle. Two groups of animals were used (ﬁve per group); one
group was injected i.p. with PB 30 mg/kg body weight, a single dose per day, over
3 days, 60 mg/kg on day 4, and b-NF 80 mg/kg, a single dose, on day 4. The animals
were killed by cervical dislocation on day 5. The second group was injected i.p. with
b-NF 80 mg/kg, a single dose; animals were killed by cervical dislocation 24 h after
inoculation. PB and b-NF are classical inducers of CYP2B and CYP1A isoforms,
respectively (Matsushima et al., 1976).2.3. Preparation of liver S9 and microsomal fractions
S9 fraction was prepared according to the procedure described by Maron and
Ames (1983). Livers were freshly excised and washed in a 0.15 M KCl solution
(3 mL/g liver wet weight). A pool of livers from each group of rats was homogenized
in the same solution and centrifuged at 9000g per 10 min. The supernatant, S9 frac-
tion, was stored at 80 C until use. To obtain the microsomal fraction, S9 was cen-
trifuged at 100,000g per 60 min; the pellet was resuspended in the initial volume
with 0.1 M phosphate buffer (pH 7.4) and 0.25 M sucrose, and centrifuged at
100,000g per 60 min. the pellet obtained (microsomal fraction), was resuspended
in 0.1 M phosphate buffer (pH 7.4), 1 mM ethylene diamine tetraacetic acid (EDTA),
0.1 mM dithiothreitol (DTT) and 20% v/v glycerol, and stored at 80 C until use.2.4. Inhibition studies in rat liver microsomes
The EROD (CYP1A1 ethoxyresorﬁn O-deethylase associated activity), MROD
(CYP1A2 methoxyresoruﬁn O-demethylase associated activity), PROD (CYP2B1
penthoxyresoruﬁn O-dealkylase associated activity) and BROD (CYP2B2 benzyloxy-
resoruﬁna O-dealkylase associated activity) were measured as described previously
(Burke et al., 1994). BG, DHB or NG was added into incubation mixtures as metan-
olic (MeOH), dimethylsulfoxide (DMSO) or aqueous solution, respectively, in a ﬁnal
concentration of MeOH and DMSO in the incubation mixture of 1%. An equal vol-
ume of MeOH and DMSO was also added to controls. An incubation mixture con-
taining one of the GJ compounds, rat liver microsomes (0.01–0.1 mg), substrate
(1 lM ER, 5 lM MR, 5 nM PR or 20 nM BR), and buffer pH 7.6 (50 mM Tris–HCl
and 25 mM MgCl2) was incubated for 3 min at 37 C. The reaction was then started
by addition of NADPH (0.5 mM) and was followed for 3 min, recording the ﬂuores-
cence signal every 15 s. Activities were calculated from a standard curve of resoru-
ﬁn (5–50 pmol/mL).2.5. Kinetic inhibition of CYP1A1 by bergamottin
CYP1A1 Supersomes and different concentrations of ER were used to deter-
mine CYP1A1 enzymatic kinetics. A typical Michaelis–Menten curve was found.
The ﬁnal reaction mixture contained: 1 pmol CYP1A1 (Supersomes), 0.5 mM
NADPH, different ER concentrations and 0, 4, 8 and 16 nM of BG. The reaction
was started with the addition of NADPH. Kinetic constants were obtained by a non-
linear regression analysis of experimental data ﬁtted to Michaelis–Menten equation
with competitive-type inhibition (Software Origin version 8.0). Kinetic analysis is
also shown by using the Lineweaver–Burk, Dixon and replot of the slopes of the
Dixon plot.2.6. Assay of mutagenicity
The Salmonella mutagenicity test was carried out as described previously (Mar-
on and Ames, 1983) using Salmonella typhimurium strain TA98, a gift from Dr. B.N.
Ames (California University, Berkeley, C.A., USA), and S9 fraction (rat hepatic S9
treated with b-NF), as the metabolic activation system. The suspension mixture
(500 lL, total volume), consisted on 4 mM NADP, S9 fraction (160 lg total protein),
8 mM MgCl2, 33 mM KCl, 5 mM glucose-6-phosphate and phosphate buffer pH 7.4,
the promutagen (25 lg of BP or 3-MC), the test compound (0–25 lg BG) and 100 lL
of S. typhimurium overnight culture; they were sequentially added to a tube con-
taining 2 mL of 45 C warm soft agar. The mixture was placed in a Petri dish con-
taining Vogel–Bonner minimal medium (15 mg/mL agar in Vogel–Bonner E
mediumwith 20 mg/mL glucose). After incubation for 2 days in the dark, the revert-
ant colonies (His+) were counted. Toxicity of the tested agents was assessed by
observing the background bacterial growth in the minimal agar plates due to traces
of histidine in the medium (De Flora et al., 1992).
Table 1
Inhibitory effect (IC50) of grapefruit juice components on the CYP associated
alkoxyresoruﬁn-O-dealkylase activity.
Inhibitor BG (lM) DHB (lM)
Enzyme
CYP1A1 0.192 ± 0.029 3.162 ± 0.153
CYP1A2 5.077 ± 0.321 54.479 ± 1.751
CYP2B1 9.495 ± 0.979 55.066 ± 3.638
CYP2B2 4.535 ± 0.092 48.195 ± 0.189
Data represent the mean ± SD from three independent experiments. IC50 is the
concentration of BG or DHB necessary to inhibit 50% of the enzyme activity.
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All the experiments described were done at least in triplicate. Data are ex-
pressed as mean ± SD. Statistical analyses were done with XLSTAT version
2010.6.01. One-way ANOVA and Tukey tests were employed for comparisons be-
tween CYP1A1 activities at different concentrations of BG.
3. Results
3.1. Inhibitory effect of NG, BG and DHB on CYP1A and CYP2B activities
The results obtained with hepatic microsomes from rats treated
with the combination of PB/b-NF shows that, at the concentrations
used (0.25–1.0 lM), NG did not display an inhibitory effect on the
activity of the tested CYP’s. On the other hand, the presence of BG
and DHB in the reaction mixture clearly decreased in a dose-
dependent way (Fig. 1) the activity of the CYP isoforms tested. Ta-
ble 1 contains the concentration of BG and DHB necessary to de-
crease 50% the activity (IC50) of the respective CYP. From these
data it is evident that BG possesses the strongest inhibitory capac-
ity and that CYP1A1 is the most susceptible protein. In order to rule
out any possible interference of NG, BG and DHB with the ﬂuores-
cence of resoruﬁn, that is the ﬁnal molecule resulting from the
activity of all the CYP´s tested, we added the highest concentrations
of each of the GJ components to each concentration of resoruﬁn
used to set the standard curve. Results indicated that neither of
the GJ components tested interfered with the ﬂuorescence of res-
oruﬁn (data not shown).
3.2. Competitive inhibition of rat CYP1A1 activity by BG
Taking into account the above mentioned results we decided to
carry out experiments in order to elucidate the type of inhibition
promoted by BG as well as its properties as chemopreventive agent
interfering with the mutagenic process. To achieve this goal we
determined the kinetic properties of rat recombinant CYP1A1
(Supersome) using ethoxyresoruﬁn as substrate in the presence
of BG, and the antimutagenic effect of BG against the well known
mutagens BP and 3-MC.
The demethylation of ER in the presence of Supersome as
described in the Materials and methods showed a typicalFig. 1. Concentration-dependent inhibitory effect of bergamottin (full shapes) and
dihydroxybergamottin (blank shapes) on the rat microsomal CYP1A1, 1A2, 2B1, and
2B2 associated alcoxyresoruﬁn-O-dealquilase activity. BG and DHB were added at
different concentrations to the incubation mixture containing rat liver microsomes
and ethoxyresoruﬁn (1 lM). The reaction was started by addition of NADPH and
followed for 3 min. recording the ﬂuorescence signal every 15 s. Activity was
calculated from a standard curve of resoruﬁn. Data represent the mean ± SD from
three independent experiments.Michaelis–Menten kinetics (Fig. 2a). A Lineweaver–Burk plot
analysis gave a Kmapp = 0.0723 ± 0.0079 lM and a Vmapp = 6.141 ±
0.255 lU/pmol protein (Fig. 2b). Based on previous tests (data not
shown) we chose BG concentrations in the range of 5 pmol–
50 nmol for the inhibition experiments and the Lineweaver–Burk
plot from these data indicated that BG is a competitive inhibitor
(Fig. 2b). In order to conﬁrm the type of BG inhibition, we followed
the criteria of inhibition types examined by Segel (1993) who says
that in a Dixon Plot for a competitive inhibitor the intersection
point is 1/m = 1/Vm and the replot of their Slopes intersects the ori-
gin. We ﬁrst obtained a Dixon plot with different concentrations of
BG vs. different concentrations of ER (Fig. 3a) and then the slopes
obtained were plotted against 1/[ER] (Fig. 3b). The results obtained
clearly deﬁned BG as a competitive inhibitor with a Kiapp =
10.703 nM.
3.3. Protective effect of BG against mutagenic damage in S.
typhimurium
The mutagenicity of B[a]P and 3-MC depends on their bioactiva-
tion by CYP1A1 y CYP1A2. With the objective to explore the biolog-
ical effect of BG as a competitive inhibitor of CYP1A, we used the
Salmonella/microsome mutagenicity assay and tested the possible
interference of BG on the mutagenicity of BP and 3-MC. The muta-
genicity of both compounds in the presence of S9 activation mix-
ture obtained from rats treated with a combination of PB/b-NF,
showed a tendency to decrease as the concentration of BG in-
creased (Fig. 4). This decrease in the number of mutants was not
accompanied by an alteration in the bacterial background lawn
compared to control plates, indicating that the results observed
were not due to bacterial toxicity.
4. Discussion
CYP inhibition by food components is implicated in at least two
scenarios: (i) food–drug-interactions leading to adverse effects and
(ii) inhibition of mutagenic/carcinogenic compounds metabolism
leading to antimutagenic/anticarcinogenic effects. Several CYP
inhibitors have been tested in animal models as chemopreventive
agents for their potential use in the prevention of cancer and other
degenerative processes. In this work we tested the ability of the
three main components of GJ to inhibit the activity of four isoforms
belonging to the CYP1 and CYP2 families that are involved in the
metabolism of mutagenic/carcinogenic xenobiotics. Among the
three GJ component tested, BG resulted with the highest inhibitory
activity with an IC50 value 16, 11, 6 and 11 times smaller than
those required by DHB to inhibit CYP1A1, 1A2, 2B1 and 2B2 respec-
tively; under the experimental conditions tested, NG did not
showed CYP inhibition activity (Table 1). The IC50 value of BG ob-
tained in this work is similar to that reported by others using rat
hepatic cell cultures, mice hepatic microsomes or human recombi-
nant enzyme (Cai et al., 1996) as sources of CYP1A and constitute
evidence for the potential chemopreventive activity of BG and its
possible interaction with drugs metabolized by CYP1A2. With
Fig. 2. CYP1A1 associated ethoxyresoruﬁn-O-deethylase activity in the absence and presence of different concentrations of BG. (A) Reaction in a ﬁnal volume of 1 ml was
followed for 1.5 min. recording the ﬂuorescence signal each 15 s; reactions consisted on 1 pmol Supersome protein, 50 mM NADPH and ethoxyresoruﬁn at different
concentrations. For the inhibition experiments, BG was added at different concentrations to the reaction mixture. (B) Lineweaver–Burk plot analysis were done to obtain the
kinetic parameters Km = 0.0723 ± 0.0079 lM; Vmapp = 6.141 ± 0.255 lU/pMol of the Supersome protein. Each point in (A) represents the mean ± SD obtained from four
independent experiments.
Fig. 3. Conﬁrmation of the CYP1A1 inhibitory properties of Bergamottin by: (A) Dixon plot and (B) replot of the slopes of the Dixon plot vs. 1/[ethoxyresoruﬁn] analysis. Each
plot in this ﬁgure a was obtained from independent reactions containing the desired concentration of ethoxyresoruﬁn (0.018–0.52 lM), 1 pM Supersome protein, 50 mM
NADPH and different concentration of bergamottin (0, 4, 8 and 16 lM) in a ﬁnal volume of 1 ml. Each reaction was followed for 1.5 min. recording the ﬂuorescence signal each
15 s. Each point in this ﬁgure A represents the mean ± SD obtained from three independent experiments. The slope of each plot in this ﬁgure A was obtained and ploted vs. the
inverse of the concentration of ethoxyresoruﬁn (B).
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pharmacokinetic interaction between GJ and theophylline was ob-
served. Nevertheless, another study gave evidence of a non-signif-
icant reduction in the theophylline pharmacokinetic parameters
occasioned by GJ (Gupta et al., 1999).Results from studies in which a comparison of the inhibitory ef-
fect of BG and DHB on CYP3A4 activity has been reported, are con-
troversial. He et al. (1998), suggested that BG is the main active
principle present in GJ; on the other hand, other studies demon-
strated that DHB is one of the main inhibitors of CYP3A4 (Ohta
Fig. 4. Antimutagenic effect of bergamottin and naringin against the mutagenicity of benzo[a]pyrene and 3-methylcholanthrene in the Salmonella typhimurium strain TA98.
Several concentrations of bergamottin were added to a tube containing molten top agar plus 0.1 ml of an overnight culture of TA98 strain, 3-methylcholanthrene (A) or
benzo[a]pyrene (B) and S9 mixture. Different concentrations of naringin were tested against benzo[a]pyrene mutagenicity (C). Each point represents the mean of revertant
colonies found in six replicated plates from two independent experiments.
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NG were important for the total inhibitory activity on CYP3A4
present in GJ (Bailey et al., 2000). Additional data reported by
Tassaneeyakul et al. (2000), suggested that furocoumarin dimers,
although present in minor concentration than BG and DHB in GJ,
were the most potent inhibitors of CYP3A4.
Our study shows that BG is the strongest inhibitor against the
activity of all the CYP isoforms evaluated, especially CYP1A1, and
that NG did not affect the activity of any of them. NG is metabo-
lized in vivo by a-ramnosidase and b-glucosidase generating nar-
ingenine the active inhibitory molecule affecting CYP3A4 activity
(Fuhr and Kummert, 1995; Kane and Lipsky, 2000). Under the
conditions of this study in which none of these enzymes were
present, there was no opportunity for NG metabolism and this
could be the reason why no inhibitory effect was obtained with
this compound.
Due to the importance of CYP1A1 in chemical carcinogenesis as
well as BG as one of the main ingredients of the widely consumed
GJ, we decided to biochemically characterize the kind of inhibition
exerted by BG. In a previous study using hepatic microsomes from
3-MC treated mice, Cai et al. (1993), demonstrated that BG is a
non-competitive inhibitor of CYP1A1 contrary to our result that
indicate BG as a competitive inhibitor. Microsomal preparations
obtained from whole liver (hepatic microsomes) contain different
CYP isoforms acting on the same substrate which may account
for a biased result obtained by Cai et al. (1993). In addition, it is
well established that alcoxyresoruﬁns used as substrates for the
determination of CYP activity, are not totally speciﬁc for a single
CYP isoform but more than one is implicated in their metabolism.
Another argument against the use of hepatic microsomes to char-
acterize the type of biochemical CYP inhibition exerted by naturalcompounds is that non-competitive kinetics might be found
(Hollenberg, 1992).
CYP1A1 is implicated in the metabolism of a wide array of
mutagenic/carcinogenic xenobiotics, therefore it could be a po-
tential target for chemopreventive studies of human populations
exposed to unusual high concentrations of carcinogenic molecules
present in the occupational environment or resulting from life-
style habits. As a ﬁrst step in testing if the inhibition of CYP by
BG results in a protective effect from genotoxic damage, we
tested its antimutagenic capacity against the well known promu-
tagens BP and 3-MC in the S. typhimurium mutagenicity test.
CYP1A subfamily is implicated in the metabolism of both promu-
tagens and inhibition of their mutagenicity could be a result of
the inhibition of their metabolism. Results in Fig. 4 shows that
BG behaved as an antimutagenic agent against BP and 3-MC
reducing the number of revertant colonies as the dose increased.
The antimutagenic potential of BG, expressed as the slope of the
curve, was similar for the two promutagens, 9.1 revertants/lg
BG and 14.8 revertants/lg BG for BP and 3-MC respectively. It
is important to note that no antimutagenic effect of NG was re-
corded when used in combination with BP in the Ames test
(Fig. 4c).
We can conclude that among the three main ingredients of GJ
tested, BG and DHB inhibited the activity of the different CYP en-
zymes evaluated; CYP1A1 was the most sensible isoform and BG
the most potent inhibitor. NG showed no inhibitory potential
against these isoforms and the biochemical analysis demon-
strated a competitive inhibition exerted by BG against CYP1A1
activity. This inhibitory activity of BG translated into an antimu-
tagenic effect against the genotoxicity of BP and 3-MC in the S.
typhimurium/microsome test. It is important to deﬁne if these
S. Olguín-Reyes et al. / Food and Chemical Toxicology 50 (2012) 3094–3099 3099properties of BG elicited in in vitro systems, can be reproduced in
in vivo models.
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